Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813873 | 0.81 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL6241506 | 0.81 | ALDH1A1 (0.44) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL28002892 | 0.79 | CA12 (0.36) | — | |
| SCHEMBL941266 | 0.77 | G6PD (0.37) | ENPP2LMNAG6PDIDESMN1; SMN2 | |
| SCHEMBL1448262 | 0.77 | SMN1; SMN2 (0.37) | ENPP2LMNAG6PDIDESMN1; SMN2 | |
| SCHEMBL27958319 | 0.76 | ENPP2 (0.38) | ENPP2LMNAG6PDIDESMN1; SMN2 | |
| SCHEMBL1447811 | 0.75 | PTGS2 (0.38) | ENPP2LMNAG6PDIDESMN1; SMN2 | |
| SCHEMBL971270 | 0.75 | LMNA (0.42) | ENPP2LMNAG6PDIDESMN1; SMN2 | |
| SCHEMBL635411 | 0.75 | G6PD (0.44) | ENPP2LMNAG6PDIDESMN1; SMN2 | |
| SCHEMBL1636862 | 0.75 | G6PD (0.36) | ENPP2LMNAG6PDIDESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695189-B2 | Chemical crosslinkers and compositions thereof | Nguyen, Mark Quang (US) | 2017-07-04 | — | — | US | claimed |
| US-20140249319-A1 | CHEMICAL CROSSLINKERS AND COMPOSITIONS THEREOF | Nguyen, Mark Quang (US) | 2014-09-04 | — | — | US | claimed |
| US-10898503-B2 | Cleavable drug conjugates, compositions thereof and methods of use | Nguyen, Mark Quang (US) | 2021-01-26 | — | — | US | disclosed |
| US-9695189-B2 | Chemical crosslinkers and compositions thereof | Nguyen, Mark Quang (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160143937-A1 | METHODS OF USING CLEAVABLE DRUG CONJUGATES AND COMPOSITIONS THEREOF | Nguyen, Mark Quang (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160129027-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-05-12 | — | — | US | disclosed |
| US-9295731-B2 | Cleavable drug conjugates, compositions thereof and methods of use | Nguyen, Mark Quang (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140294851-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | Nguyen, Mark Quang (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140249319-A1 | CHEMICAL CROSSLINKERS AND COMPOSITIONS THEREOF | Nguyen, Mark Quang (US) | 2014-09-04 | — | — | US | disclosed |
| US-20080044350-A1 | Optical Imaging Contrast Agents for Imaging Lung Cancer | GE HEALTHCARE AS (NO) | 2008-02-21 | — | — | US | disclosed |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | AMERSHAM HEALTH AS (NO) | 2007-09-13 | — | — | US | disclosed |
| EP-1667734-A2 | OPTICAL IMAGING OF COLORECTAL CANCER | GE Healthcare AS (NO) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005058370-A1 | OPTICAL IMAGING CONTRAST AGENTS FOR IMAGING LUNG CANCER | AMERSHAM HEALTH AS (NO) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005030266-A2 | OPTICAL IMAGING OF COLORECTAL CANCER | AMERSHAM HEALTH AS (NO) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129027-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | PAICS, FOLH1, DHFR | ENPP2 548/4885LMNA 925/4885G6PD 791/4885 |
| US-10898503-B2 | Cleavable drug conjugates, compositions thereof and methods of use | PAICS, FOLH1, DHFR | ENPP2 548/4885LMNA 925/4885G6PD 791/4885 |
| US-20140249319-A1 | CHEMICAL CROSSLINKERS AND COMPOSITIONS THEREOF | CBR3, ERCC5, LIG3 | ENPP2 2322/4885LMNA 2767/4885G6PD 1062/4885 |
| US-20080044350-A1 | Optical Imaging Contrast Agents for Imaging Lung Cancer | KLK3, ROCK1, SMO | ENPP2 390/4885LMNA 3488/4885G6PD 3660/4885 |
| US-20140294851-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | PAICS, FOLH1, DHFR | ENPP2 548/4885LMNA 925/4885G6PD 791/4885 |
| US-20160143937-A1 | METHODS OF USING CLEAVABLE DRUG CONJUGATES AND COMPOSITIONS THEREOF | SI, PAICS, FURIN | ENPP2 784/4885LMNA 450/4885G6PD 410/4885 |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | IQGAP1, AQP3, ROCK1 | ENPP2 352/4885LMNA 3331/4885G6PD 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.